We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Dentsply (XRAY) Q4 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts forecast that Dentsply International (XRAY - Free Report) will report quarterly earnings of $0.28 per share in its upcoming release, pointing to a year-over-year increase of 7.7%. It is anticipated that revenues will amount to $920.05 million, exhibiting an increase of 1.7% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Dentsply metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Net sales- Essential Dental Solutions' will reach $348.19 million. The estimate indicates a change of +0.6% from the prior-year quarter.
Analysts' assessment points toward 'Net sales- Orthodontic and Implant Solutions' reaching $196.84 million. The estimate indicates a change of +6.4% from the prior-year quarter.
According to the collective judgment of analysts, 'Net sales- Connected Technology Solutions' should come in at $284.22 million. The estimate indicates a change of -3% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net sales- Wellspect Healthcare' will likely reach $86.48 million. The estimate indicates a change of +6.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net sales- Orthodontic and Implant Solutions- Implants & Prosthetics' should arrive at $161.59 million. The estimate suggests a change of -0.3% year over year.
The collective assessment of analysts points to an estimated 'Net sales- Connected Technology Solutions- CAD/CAM' of $128.39 million. The estimate indicates a year-over-year change of -9.6%.
Analysts forecast 'Net sales- Connected Technology Solutions- Equipment & Instruments' to reach $161.37 million. The estimate indicates a change of +6.9% from the prior-year quarter.
The consensus among analysts is that 'Net sales- Orthodontic and Implant Solutions- Orthodontics' will reach $35.14 million. The estimate indicates a change of +52.8% from the prior-year quarter.
Analysts expect 'Revenues- United States' to come in at $264.91 million. The estimate indicates a year-over-year change of +2.3%.
It is projected by analysts that the 'Revenues- Rest of World' will reach $242.88 million. The estimate points to a change of +2.1% from the year-ago quarter.
The consensus estimate for 'Revenues- Europe' stands at $420.19 million. The estimate points to a change of +3% from the year-ago quarter.
The average prediction of analysts places 'Adjusted Operating Income- Connected Technology Solutions' at $20.97 million. Compared to the current estimate, the company reported $49.00 million in the same quarter of the previous year.
Shares of Dentsply have experienced a change of +2.9% in the past month compared to the -0.3% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), XRAY is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Dentsply (XRAY) Q4 Earnings, Beyond Revenue and EPS
Wall Street analysts forecast that Dentsply International (XRAY - Free Report) will report quarterly earnings of $0.28 per share in its upcoming release, pointing to a year-over-year increase of 7.7%. It is anticipated that revenues will amount to $920.05 million, exhibiting an increase of 1.7% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Dentsply metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Net sales- Essential Dental Solutions' will reach $348.19 million. The estimate indicates a change of +0.6% from the prior-year quarter.
Analysts' assessment points toward 'Net sales- Orthodontic and Implant Solutions' reaching $196.84 million. The estimate indicates a change of +6.4% from the prior-year quarter.
According to the collective judgment of analysts, 'Net sales- Connected Technology Solutions' should come in at $284.22 million. The estimate indicates a change of -3% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net sales- Wellspect Healthcare' will likely reach $86.48 million. The estimate indicates a change of +6.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net sales- Orthodontic and Implant Solutions- Implants & Prosthetics' should arrive at $161.59 million. The estimate suggests a change of -0.3% year over year.
The collective assessment of analysts points to an estimated 'Net sales- Connected Technology Solutions- CAD/CAM' of $128.39 million. The estimate indicates a year-over-year change of -9.6%.
Analysts forecast 'Net sales- Connected Technology Solutions- Equipment & Instruments' to reach $161.37 million. The estimate indicates a change of +6.9% from the prior-year quarter.
The consensus among analysts is that 'Net sales- Orthodontic and Implant Solutions- Orthodontics' will reach $35.14 million. The estimate indicates a change of +52.8% from the prior-year quarter.
Analysts expect 'Revenues- United States' to come in at $264.91 million. The estimate indicates a year-over-year change of +2.3%.
It is projected by analysts that the 'Revenues- Rest of World' will reach $242.88 million. The estimate points to a change of +2.1% from the year-ago quarter.
The consensus estimate for 'Revenues- Europe' stands at $420.19 million. The estimate points to a change of +3% from the year-ago quarter.
The average prediction of analysts places 'Adjusted Operating Income- Connected Technology Solutions' at $20.97 million. Compared to the current estimate, the company reported $49.00 million in the same quarter of the previous year.
View all Key Company Metrics for Dentsply here>>>Shares of Dentsply have experienced a change of +2.9% in the past month compared to the -0.3% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), XRAY is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .